2nd Raw Materials for Cell and Gene Therapy Summit | October 7-9, Boston, MA

Securing High Grade Raw Materials for a Smoother Supply Chain...

Unlock the future of cell and gene therapy manufacturing at the 2nd Raw Materials for Cell and Gene Therapy Summit. This is your exclusive opportunity to hear directly from regulatory and standards leaders such as Andrew Sarafanov (FDA) and Rebecca Potts (USP), as they share the latest thinking on BLA review expectations, raw material characterization, and the evolving global standards landscape.

With the cell and gene therapy industry facing increasing complexity and supply chain uncertainty, top innovators from Vertex, Genentech, and Bristol Myers Squibb will reveal how they're reengineering supplier strategies, through dual sourcing, co-development, and rigorous vendor qualification.

Explore real-world solutions to qualification challenges and variability risks with insights from Ultragenyx, Abeona Therapeutics, and Metagenomi. Through hands-on workshops, strategic roundtables, and high-impact networking, you'll walk away with the connections and frameworks needed to strengthen your quality programs and stay ahead of regulatory expectations. The time to align, adapt, and advance is now.

Speakers: Aida Rouzmehr Material Science Product Lead Genentech, Andreas Beckhaus President ProDeMaCon LLC Consulting, Andrey Sarafanov Principal Investigator and Head of Research Laboratory FDA, Basak Clements Independent Raw Materials Expert, Benjamin Espen Principal Quality Engineer Avobis Bio, Charles Burt Senior Manager, Quality and Supplier Abeona Therapeutics, David Cady Principal Consultant, Pharma Raw Material Program Management ProDeMaCon LLC Consulting, Dawn Henke Executive Director Standards Coordinating Body, Faryar Tavakoli Independent Raw Material Expert, Grace Perry Global Procurement Specialist Roche, Jose Caraballo Independent Raw Materials Expert, Julien Camperi Senior Principal Scientist, Gene and Cell Therapy Genentech, Kok-Seong Lim Senior Director, Analytical Sciences and Quality Control Metagenomi, Lili Belcastro Associate Director Bristol Myers Squibb, Naeem Sarwar Associate Director, Manufacturing Science and Technology Vertex Pharmaceuticals, Piyush Vyas Manager, CAR-T Supply Planner Buyer Bristol Myers Squibb, Scott Jeffers Chief Technology Officer GenSight Biologics, Stephen Yi Senior Director, Manufacturing, Science and Technology Ultragenyx Pharmaceutical Inc., Thomas Liu Principal Scientist Adaptimmune Therapeutics plc., Vladimir Slepushkin Chief Technology Officer MedTherapy Biotechnology